SELLAS Life Sciences Group, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +5.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.05 | not reported | not reported | |
| Q1 FY26 | $-0.06 | $-0.05 | +16.7% | Beat | |
| Q4 FY25 | not reported | $-0.05 | not reported | not reported | |
| Q3 FY25 | $-0.06 | $-0.06 | +5.3% | Beat | |
| Q2 FY25 | $-0.08 | $-0.07 | +16.0% | Beat | |
| Q1 FY25 | $-0.10 | $-0.07 | +30.0% | Beat | |
| Q4 FY24 | $-0.11 | $-0.08 | +27.3% | Beat | |
| Q3 FY24 | $-0.13 | $-0.10 | +23.1% | Beat | |
| Q2 FY24 | $-0.16 | $-0.13 | +18.8% | Beat | |
| Q1 FY24 | $-0.16 | $-0.21 | -31.3% | Miss | |
| Q4 FY23 | not reported | $-0.25 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.33 | not reported | not reported |
Back to SLS overview · SLS holders · SLS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.